Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 1, 2022, Acumen Pharmaceuticals, Inc. (the “Company”) amended and restated its employment agreements (each an “A&R Employment Agreement” and together the “A&R Employment Agreements”) for the following executive officers: i) Daniel O’Connell, Chief Executive Officer, ii) Matt Zuga, Chief Financial Officer and Chief Business Officer, iii) Eric Siemers, Chief Medical Officer and iv) Russell Barton, Chief Operating Officer. The following paragraphs provide a summary of the A&R Employment Agreements.
Employment Agreement with Daniel O’Connell
Under the terms of Mr. O’Connell’s A&R Employment Agreement (the “CEO A&R Employment Agreement”), his annual base salary is $551,200 and the annual target for his annual performance bonus (the “Annual Bonus”) is fifty-five percent (55%) of Mr. O’Connell’s then-current base salary (the “CEO Target Amount”). Under the CEO A&R Employment Agreement, Mr. O’Connell’s eligibility for the CEO Annual Bonus will be based upon the board of directors (the “Board”) of the Company’s assessment of Mr. O’Connell’s and the Company’s attainment of individual and corporate performance goals as determined by the Board, or any committee thereof, in its sole discretion. Additionally, the CEO A&R Employment Agreement provides that Mr. O’Connell shall be eligible to be considered for future equity awards as may be determined by the Board, or the Company’s compensation committee of the Board, in its sole discretion, and in accordance with any applicable equity plans or arrangements that may be in effect from time to time.
Pursuant to the terms of the CEO A&R Employment Agreement, Mr. O’Connell’s employment is at will and may be terminated at any time by the Company or Mr. O’Connell. If Mr. O’Connell’s employment is terminated by the Company without Cause (as defined in the A&R Employment Agreements) or by Mr. O’Connell for Good Reason (as defined in the A&R Employment Agreements), then Mr. O’Connell would be eligible to receive the following severance benefits, less applicable tax withholding (the “Non-CIC Severance Benefits”):
| | • | | payment of his then-current base salary in accordance with normal payroll procedures for twelve (12) months; |
| | • | | payment or reimbursement of continued health coverage for Mr. O’Connell and his dependents under COBRA for the applicable severance period; and |
| | • | | payment of any i) accrued but unpaid salary through the date of termination; ii) unreimbursed business expenses incurred by Mr. O’Connell in accordance with the Company’s standard reimbursement policies, and iii) benefits owed to Mr. O’Connell under any qualified retirement plan or health and welfare benefit plan in which Mr. O’Connell was a participant in accordance with applicable law and the provisions of such plan (together, the “Accrued Obligations”). |
Under the CEO A&R Employment Agreement, if Mr. O’Connell’s employment is terminated by the Company without Cause or if Mr. O’Connell resigns for Good Reason, in either case within three (3) months prior to or twelve (12) months following the effective date of a Change in Control (as defined in the A&R Employment Agreements), then Mr. O’Connell would be entitled to the following severance benefits, less applicable tax withholding (the “CIC Severance Benefits”):
| | • | | payment of his then-current base salary in accordance with normal payroll procedures for eighteen (18) months; |
| | • | | payment or reimbursement of continued health coverage for Mr. O’Connell and his dependents under COBRA for the applicable severance period; |
| | • | | a lump sum cash payment of 1.5 times the CEO Target Amount for the year in which the termination occurs in accordance with normal payroll procedures; |
| | • | | the vesting and exercisability of all outstanding equity awards held by Mr. O’Connell immediately prior to the termination date that are subject to time-based vesting requirements (if any) will be accelerated in full, and the vesting and exercisability of all outstanding equity awards subject to performance-based vesting will be treated as set forth in Mr. O’Connell’s equity award agreement governing such award; and |
| | • | | payment of any Accrued Obligations. |
